Participate in a Migraine Research Study
If you or someone you love has been diagnosed with Migraine, consider participating in a clinical research study.
Participants receive a high standard of care, and health insurance is not necessary to participate. Patients who qualify for our clinical trials receive all study-related care and treatment at no cost. In some cases, you may be compensated for your time and travel. You may even gain access to research treatments before they become widely available.
Interested in learning more? Contact Premiere Research Institute at (561) 296-3816, or fill out the form below.
Without volunteers for clinical trials, improved treatments, including a cure for migraines could never become a reality.
The ultimate goal of migraine research is the relief of all migraine episodes. Today it is possible for this to be accomplished in a small percentage of people and ultimately we hope to vastly improve the percentage over the next several years.
Today we do have new treatments primarily because we have a greater understanding of how a migraine is caused. Some of our latest research focuses on controlling the neuropeptide called calcitonin gene related peptide [CGRP]. If we can block this neurotransmitter from working we can significantly influence the potential for a migraine to develop. Today we are studying compounds that can block CGRP at the molecular level.
- BHV3000 acute pediatric migraine website: www.pediatricmigrainestudy.com
- Recruitment slides are attached and here is the link to the 28 minute video: https://vimeo.com/647850380/8cec5bf441
- IRB approved social media content: https://www.youtube.com/playlist?list=PLydt7QQniV-DD41RG08ICuXuxEdZNMOD4
Articles about Migraines
To read one of our most recent articles about Migraines just click the title of the article.
Novel Drug Shown to Reduce Pain and Disability in Acute Migraine
A novel treatment option for acute migraine that is currently under review by the Food and Drug Administration (FDA) has shown promising results in the reduction of pain and disability in acute migraine sufferers. The drug ubrogepant, developed by Allergen, is a small...
The Future of Preventative Migraine Treatment
Over the past decade, there has been a significant amount of progress made in the development of new preventative migraine therapies that differ from previous treatment types. One such breakthrough was the recent FDA approval of medications in a novel class of drugs...
Managing Common Migraine Triggers
Most people who experience migraine headaches have a number of triggers which can kick-start an acute episode. By understanding what these triggers are, migraine sufferers can make lifestyle adjustments that can help to prevent or minimize the frequency and severity...
A New Strategy for Preventing Migraine: Anti-CGRP Therapies
A new and unique class of preventive migraine treatments have been approved by the FDA over the past year which have several benefits over older medications for the prevention of migraine. Anti-CGRP medicines, which are monoclonal antibodies, block the activity of...
The State of Current Migraine Treatments
Today there are more treatment options available for people who suffer from migraine than ever before. As a result, people with migraine are now better able to manage their symptoms due to the variety of therapies available, whether through drug or non-drug...
What are the Differences Between a Migraine and a Tension Headache?
Migraine and tension headaches are often painful, but there are notable differences between them that many people are unaware of. It is important to know what these differences are, as they can be pivotal in deciding to seek out a proper diagnosis and treatment. While...
Anti-CGRP Migraine Drug Shows Promising Symptom Relief
A new small molecule calcitonin gene-related peptide (CGRP) drug in phase 3 clinical trials has shown promising relief of migraine symptoms when administered as an acute single-dose treatment. The migraine drug, Rimegepant, relieved pain and other bothersome migraine...
The Impact of Migraine at Work
A large global survey of migraine patients which included over 11,000 respondents from 31 countries found that many migraine sufferers commonly deal with functional impairments at work due to their symptoms. Respondents of the survey had at least four migraine days...
Erenumab (Aimovig) FDA Approved as First Anti-CGRP Migraine Drug
Adults with migraine now have an additional preventative treatment option available to them, thanks to a new and unique migraine medication that has been approved by the Food and Drug Administration (FDA). Aimovig (erenumab-aooe) is a novel, first of its kind...
Current Migraine Prevention Strategies
Today, there are a variety of different migraine prevention options which can help ease the lifestyle burdens that migraine sufferers often live with. There are several goals to migraine prevention, such as a lessening of functional impairments and disability,...
To view a brief description of the specialties and background of each of our physicians click on their name.